Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07496463
PHASE2
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Sponsor: Massachusetts General Hospital
View on ClinicalTrials.gov
Summary
The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
1
Start Date
2026-04-01
Completion Date
2026-10-01
Last Updated
2026-04-01
Healthy Volunteers
No
Conditions
Interventions
DRUG
Setmelanotide
Setmelanotide will be prescribed at the standard initial dose of 2 mg SC daily. The treatment will be uptitrated at the 2-Week visit to 3 mg SC daily if tolerated. We will continue this maximal dose for a period of 6 months.
Locations (1)
Massachusetts General Hospital
Boston, Massachusetts, United States